Asian Journal of Transfusion Science
Home About Journal Editorial Board Search Current Issue Ahead of print Back Issues Instructions Subscribe Login  Users: 59 Print this page  Email this page Small font sizeDefault font sizeIncrease font size 

EDITORIAL Table of Contents   
Year : 2016  |  Volume : 10  |  Issue : 1  |  Page : 1-2
National blood donor vigilance programme: India

1 National Institute of Biologicals, Ministry of Health and Family Welfare, Government of India, Noida, Uttar Pradesh, India
2 Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, Punjab and Haryana, India

Click here for correspondence address and email

Date of Web Publication1-Feb-2016

How to cite this article:
Bisht A, Singh S, Marwaha N. National blood donor vigilance programme: India. Asian J Transfus Sci 2016;10:1-2

How to cite this URL:
Bisht A, Singh S, Marwaha N. National blood donor vigilance programme: India. Asian J Transfus Sci [serial online] 2016 [cited 2023 Jan 28];10:1-2. Available from:

   Introduction Top

Donor "hemovigilance" includes all activities that contribute to improving the health outcomes for blood donors as well as safety and effectiveness of blood donation for purposes of medical treatment of patients. [1] Usually, blood donation is a safe procedure; however, a small percentage of donors may experience an adverse event (AE). Mild vasovagal reaction is the most frequent AE. It has been documented in various studies that 2-6% of donors experience an AE, but only 0.08-0.3% have a syncopal reaction where there is a loss of consciousness. [2],[3],[4]

The national data on complications of blood donation has lagged behind vigilance regarding adverse transfusion reaction in the recipient of blood transfusion. The European Commission in its guidance on reportable serious transfusion reactions and serious AEs in the transfusion chain has encouraged reporting of serious donor adverse reactions on a voluntary basis. [5] In the USA, deaths associated with blood transfusion (including whole blood donations, plasma donations and other automated donations) are subject to mandatory reporting to the Food and Drug Administration (FDA) that publishes the finding annually. [6]

Hemovigilance is a comprehensive process and is defined as "A set of surveillance procedures covering the whole blood transfusion chain from the collection of the blood and its components to the follow-up of its recipients, intended to collect and access information on unexpected or undesirable effects resulting from the therapeutic use of labile blood products, and to prevent its occurrence and reoccurrence." [7] , i.e., from the vein of the donor to the vein of the recipient.

National blood donor vigilance programme

The recipient's part, i.e., reporting of "adverse reactions" with respect to (w.r.t) blood transfusion in the patient was covered under the Haemovigilance Programme of India (HvPI) with the launch of centralized hemovigilance program on December 10, 2012 in the country. [8] As per the road map of the HvPI, donor vigilance, i.e., reporting of adverse reactions associated with blood donation was planned to be initiated by the year 2017. However, with the success of the HvPI it was decided to undertake donor vigilance activity this year itself. Hence, a National Blood Donor Vigilance Programme (NBDVP) was launched on June 14, 2015 on the World Blood Donor Day at Science City Kolkata, West Bengal, India.

The objectives of the NBDVP are to:

The road map of NBDVP includes:

A one page Adverse Donor Reaction Reporting Form (ADRRF) has been devised to capture information about adverse reactions or complications related to blood donation. The form is in line with the complications defined in the Standard for Surveillance of Complications Related to Blood Donation by working group on "donor vigilance" of the International Society of Blood Transfusion of Haemovigilance (ISBT) Working Party on Haemovigilance, December 11, 2014. [9]

The centers enrolled under the HvPI will collect data in respect of adverse reactions associated with blood donation. The information collected in ADRRF will be forwarded to the coordinating center, i.e., the National Institute of Biologicals (NIB) through a software developed in-house by NIB Information Technology division. This data will be collated and analyzed to identify trends and recommend best practices and interventions required to improve donor safety. These recommendations will be forwarded to the Drugs Controller General (India), Central Drugs Standard Control Organization, to formulate safety-related regulatory decisions to improve donor safety and satisfaction.

   Conclusion Top

National Blood Donor Vigilance Programme (NBDVP) is an integral part of the HvPI and is a comprehensive, centralized, and well-structured approach to collect, collate, and analyze data to continuously improve donor safety and satisfaction so that the blood donors have a feeling of being well-treated and well taken care of that may cause blood donors to continue as repeat donors and will have an positive impact on the National Blood Supply.

   References Top

Wiersum-Osselton JC, de Kort W, Marijt-van der Kreek T, de Wit J. Chapter 4. Setting up or consolidating a system for donor haemovigilance at the level of a blood establishment. In: De Vries RR, Faber JC, editors. Haemovigilance: An Effective Tool for Improving Transfusion Safety. Singapore: Wiley-Blackwell; 2012. p. 21-35.  Back to cited text no. 1
Lin JT, Ziegler DK, Lai CW, Bayer W. Convulsive syncope in blood donors. Ann Neurol 1982;11:525-8.  Back to cited text no. 2
Newman BH. Donor reactions and injuries from whole blood donations. Transfus Med Rev 1997;11:64-75.  Back to cited text no. 3
Trouern-Trend JJ, Cable RG, Badon SJ, Newman BH, Popovsky MA. A case-controlled multicenter study of vasovagal reactions in blood donors: Influence of sex, age, donation status, weight, blood pressure, and pulse. Transfusion 1999;39:316-20.  Back to cited text no. 4
European Commission: Common approach for definition of reportable serious adverse events and reactions as laid down in the Directive 2002/98/EC 1 (The Blood Directive) and Commission Directive 2005/61EC 2 ; version 5 (2014) SANCO/D4/IH.  Back to cited text no. 5
Fatalities Reported to FDA Following Blood Collection and Transfusion, Annual Summary for Fiscal Year 2014. Available from: [Last accessed on 2015 Nov 2].  Back to cited text no. 6
International Haemovigilance Network. Available from: . [Last accessed on 2015 Nov 2].  Back to cited text no. 7
Bisht A, Singh S, Marwaha N. Hemovigilance progam-India. Asian J Transfus Sci 2013;7:73-4.  Back to cited text no. 8
[PUBMED]  Medknow Journal  
Standard for Surveillance of Complications Related to Blood Donation, Working Group on Donor Vigilance of the International Society of Blood Transfusion Working Party on Haemovigilancein collaboration with The International Haemovigilance Network The AABB Donor Haemovigilance Working Group, December 11, 2014,  Back to cited text no. 9

Correspondence Address:
Akanksha Bisht
129, Agroha Kunj, Sector 13, Rohini, Delhi-110085
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-6247.175384

Rights and Permissions

This article has been cited by
1 Implementing Haemovigilance in India as a National Perspective
Vignesh Mano, Raman S. Kumar
Applied Clinical Research, Clinical Trials and Regulatory Affairs. 2020; 7(1): 30
[Pubmed] | [DOI]



    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


 Article Access Statistics
    PDF Downloaded115    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

Association Contact us | Sitemap | Advertise | What's New | Copyright and Disclaimer | Privacy Notice

2006 - Asian Journal of Transfusion Science | Published by Wolters Kluwer - Medknow
Online since 10th November, 2006